Literature DB >> 8922341

High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model.

Q Song1, J Chao, L Chao.   

Abstract

We established a unique transgenic mouse model in liver-targeted expression of human tissue kallikrein using a mouse albumin enhancer and promoter. Northern blot analysis and ELISA showed that human tissue kallikrein was predominantly expressed in the liver of transgenic mice and secreted into the circulation at a high level. The transcript was also detected in the kidney, pancreas, salivary gland and heart at a low level by reverse transcription-polymerase chain reaction followed by Southern blot analysis. Systolic blood pressures were measured by the tail-cuff method, all three independent transgenic mouse lines are hypotensive (84.6 +/- 1.0 mmHg, n = 17; 84.5 +/- 1.5 mmHg, n = 9; 83.1 +/- 0.8 mmHg, n = 13, P < 0.01) compared with the control mice (100.9 +/- 0.9 mmHg, n = 17). Administration of aprotinin, a potent tissue kallikrein inhibitor or Hoe 140, a bradykinin receptor antagonist, restored the blood pressure of transgenic mice but had no significant effect on control littermates. These studies show that over-production of tissue kallikrein in the circulation plays a role in blood pressure regulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922341     DOI: 10.3109/10641969609081030

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  2 in total

1.  Bradykinin regulation of salt transport across mouse inner medullary collecting duct epithelium involves activation of a Ca(2+)-dependent Cl(-) conductance.

Authors:  H Kose; S H Boese; M Glanville; M A Gray; C D Brown; N L Simmons
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Functional role of kallikrein 6 in regulating immune cell survival.

Authors:  Isobel A Scarisbrick; Benjamin Epstein; Beth A Cloud; Hyesook Yoon; Jianmin Wu; Danielle N Renner; Sachiko I Blaber; Michael Blaber; Alexander G Vandell; Alexandra L Bryson
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.